Clinical Trial Update: A Study of Foretinib in Patients With Recurrent/Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for foretinib in patients with recurrent/metastatic breast cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Foretinib (foretinib)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Recurrent Breast Cancer | Phase 2 | Status: COMPLETED